Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Purple Biotech Ltd's Competitiveness

Name: Purple Biotech Ltd Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Purple Biotech Ltd (PPBT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2024

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/PPBT/competitors                    

                        https://api.csimarket.com/api/v1/companies/PPBT/relationships                    

                        https://api.csimarket.com/api/v1/companies/PPBT/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Purple Biotech Ltd's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Purple Biotech Ltd	-	-	-	-
High-Confidence Competitors (2)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

PPBT Stock Performance relative to its Competitors

PPBT Competitors (weighted) Percent change over the selected range

Purple Biotech Ltd's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(0 of 2)

Similar-Size
(1 of 5)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Purple Biotech Ltd	-75.50 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (2)	40.4%	63.2%
Similar-Size Competitors (5)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Purple Biotech Ltd's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

PPBT Stock Performance relative to High-Confidence Competitors

PPBT High-Confidence Competitors (equal-weighted, 2) Percent change over the selected range

PPBT Stock Performance relative to Similar-Size Competitors

PPBT Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Purple Biotech Ltd's Comment on Competition and Industry Peers

The company operates in a competitive environment that includes pharmaceutical and biotechnology firms, universities, governmental entities, and others, many of which possess greater research and development capabilities, human resources, budgets, and marketing, manufacturing, financial, and managerial resources. Competitors with leading therapeutic candidates include IM1240, IM1305, CM24, and NT219. Acquisitions or investments by large corporations in competing companies may further enhance these competitors' resources. The company's clinical trials also compete with other trials for therapeutic candidates within the same therapeutic areas, potentially reducing patient availability and delaying trial progress. Additionally, established alternative therapies for the targeted diseases and conditions may limit market acceptance of the company's products.

Competitor data is not yet available for Purple Biotech Ltd.

Purple Biotech Ltd's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Phunware Inc	Named by the company	85%	2022 to 2026	3
Tvardi Therapeutics Inc	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Purple Biotech Ltd's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.